Fairtree Asset Management Pty Ltd Makes New $1.07 Million Investment in United Therapeutics Corporation $UTHR

Key Points

• Fairtree Asset Management acquired 1,976 shares of United Therapeutics worth approximately $1.07 million in the second quarter. Institutional investors collectively own 94.08% of the company.
• United Therapeutics beat quarterly earnings expectations, reporting $7.27 EPS versus the $6.86 consensus estimate, although revenue fell 1.9% year over year to $783.3 million and missed forecasts.
• Wall Street maintains a favorable view, with 11 Buy ratings and two Holds, an overall “Moderate Buy” consensus, and an average price target of $646 versus the reported share price of $521.

Fairtree Asset Management Pty Ltd acquired a new position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,976 shares of the biotechnology company's stock, valued at approximately $1,071,000.

Several other hedge funds also recently added to or reduced their stakes in the stock. Advisors Capital Management LLC acquired a new position in shares of United Therapeutics during the second quarter worth about $457,000. Vise Technologies Inc. purchased a new stake in shares of United Therapeutics in the second quarter worth about $899,000. E Fund Management Co. Ltd. acquired a new stake in shares of United Therapeutics in the second quarter valued at about $413,000. Edmond DE Rothschild Holding S.A. acquired a new stake in shares of United Therapeutics in the second quarter valued at about $459,000. Finally, Johnson Financial Group Inc. purchased a new stake in shares of United Therapeutics during the 2nd quarter valued at about $289,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $521.00 on Friday. The stock has a market cap of $22.35 billion, a price-to-earnings ratio of 18.64, a price-to-earnings-growth ratio of 1.79 and a beta of 0.59. United Therapeutics Corporation has a one year low of $302.19 and a one year high of $609.35. The business's 50-day simple moving average is $533.74 and its 200 day simple moving average is $537.53.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating analysts' consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. During the same quarter last year, the firm earned $6.41 EPS. United Therapeutics's quarterly revenue was down 1.9% on a year-over-year basis. On average, equities research analysts predict that United Therapeutics Corporation will post 26.33 EPS for the current year.

Insider Activity at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 9,500 shares of the firm's stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $547.62, for a total transaction of $5,202,390.00. Following the completion of the sale, the chief executive officer owned 40,513 shares of the company's stock, valued at approximately $22,185,729.06. This trade represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $546.28, for a total transaction of $5,462,800.00. Following the completion of the sale, the chief financial officer owned 18,876 shares of the company's stock, valued at approximately $10,311,581.28. This trade represents a 34.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 434,275 shares of company stock valued at $234,984,268. Company insiders own 8.60% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently commented on UTHR. JPMorgan Chase & Co. boosted their price target on United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a research report on Thursday, July 23rd. Royal Bank Of Canada dropped their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a research note on Thursday, August 6th. Weiss Ratings raised shares of United Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research report on Thursday, August 13th. TD Cowen reissued a "buy" rating on shares of United Therapeutics in a research report on Thursday, May 21st. Finally, Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a research note on Thursday, August 6th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $646.00.

United Therapeutics Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source